UBS Asset Management Americas Inc. reduced its stake in shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 11.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 772,545 shares of the biopharmaceutical company’s stock after selling 96,884 shares during the period. UBS Asset Management Americas Inc. owned 0.34% of Alexion Pharmaceuticals worth $94,667,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. Investors Capital Advisory Services boosted its stake in Alexion Pharmaceuticals by 0.7% in the second quarter. Investors Capital Advisory Services now owns 1,996 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 14 shares in the last quarter. Navellier & Associates Inc boosted its stake in Alexion Pharmaceuticals by 0.5% in the second quarter. Navellier & Associates Inc now owns 3,477 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 17 shares in the last quarter. Bremer Trust National Association boosted its stake in Alexion Pharmaceuticals by 0.5% in the third quarter. Bremer Trust National Association now owns 5,478 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 26 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in Alexion Pharmaceuticals by 0.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 5,691 shares of the biopharmaceutical company’s stock valued at $598,000 after buying an additional 43 shares in the last quarter. Finally, MSI Financial Services Inc boosted its stake in Alexion Pharmaceuticals by 1.0% in the third quarter. MSI Financial Services Inc now owns 4,290 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 44 shares in the last quarter. Hedge funds and other institutional investors own 94.85% of the company’s stock.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 119.38 on Tuesday. Alexion Pharmaceuticals Inc. has a 12 month low of $110.56 and a 12 month high of $193.45. The firm has a market capitalization of $26.76 billion, a P/E ratio of 72.79 and a beta of 1.45. The stock has a 50 day moving average price of $122.56 and a 200 day moving average price of $128.72.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The company earned $799 million during the quarter, compared to analyst estimates of $787.07 million. During the same quarter in the previous year, the business earned $1.16 EPS. The firm’s revenue was up 19.9% on a year-over-year basis. On average, analysts expect that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current year.

WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/29/ubs-asset-management-americas-inc-has-94667000-position-in-alexion-pharmaceuticals-inc-alxn.html.

Several analysts recently commented on the company. Piper Jaffray Cos. set a $176.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 6th. Vetr lowered Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price target for the company. in a research note on Wednesday, August 3rd. Jefferies Group reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 9th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, November 7th. Finally, Wedbush increased their price target on Alexion Pharmaceuticals from $132.00 to $135.00 and gave the company a “neutral” rating in a research note on Friday, October 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $173.36.

In related news, EVP Carsten Thiel sold 1,000 shares of the company’s stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $125.94, for a total value of $125,940.00. Following the completion of the transaction, the executive vice president now directly owns 40,579 shares of the company’s stock, valued at approximately $5,110,519.26. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Julie O’neill sold 650 shares of the company’s stock in a transaction on Friday, September 2nd. The stock was sold at an average price of $126.29, for a total transaction of $82,088.50. Following the completion of the transaction, the executive vice president now directly owns 35,384 shares of the company’s stock, valued at $4,468,645.36. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.